标题：扩张型心肌病患者神经内分泌抑制治疗调查分析

      作者：谢新苗 1，李静 2
    (1.南京医科大学附属无锡市第二人民医院药剂科，江苏 无锡 214002；
2.南京医科大学附属无锡市人民医院药剂科，江苏 无锡 214023)

      卷次： 2016年27卷18期

      【摘要】 目的 调查某院扩张型心肌病患者神经内分泌抑制治疗的情况。方法 选取无锡市人民医院2014
年 1月至 2015年 12月收治的扩张型心肌病患者，对患者三类神经内分泌抑制剂即血管紧张素转换酶抑制剂
(ACEI)/血管紧张素受体拮抗剂(ARB)、β-受体阻滞剂(βB)和醛固酮受体拮抗剂(MRA)的使用情况进行回顾性分
析。结果 332例患者中，ACEI/ARB、β-受体阻滞剂和MRA的使用率分别为85.9%、74.7%、94.7%，三类药物联合
使用率为 56.9%。三类药物均在推荐用量内给药，剂量达标率ACEI/ARB 69.3%、β-受体阻滞剂 42.0%、MRA
100.0%。结论 我院三类神经内分泌抑制剂在扩张型心肌病患者中使用率较高，但ACEI/ARB和β-受体阻滞剂的
联合用药率及剂量达标率偏低。

      【关键词】 扩张型心肌病；心力衰竭；神经内分泌抑制剂

      【中图分类号】 R542.2 【文献标识码】 D 【文章编号】 1003—6350（2016）18—3065—04


Analysis on usage of neuroendocrine inhibitors in patients with dilated cardiomyopathy.
XIE Xin-miao 1, LI Jing 2.
1. Department of Pharmacy, Wuxi No.2 People's Hospital, Nanjing Medical University, Wuxi 214002, Jiangsu, CHINA; 2.
Department of Pharmacy, Wuxi People's Hospital, Nanjing Medical University, Wuxi 214023, Jiangsu, CHINA

【Abstract】 Objective To investigate the usage of neuroendocrine inhibitors in patients with dilated cardiomy-
opathy. Methods The usage of three types of neuroendocrine inhibitors, including angiotensin converting enzyme in-
hibitor (ACEI) or angiotensin Ⅱ receptor blocker (ARB), β-blocker and aldosterone receptor antagonist (MRA), in 332
cases of patients with dilated cardiomyopathy, who admitted to our hospital from January 2014 to December 2015, were
retrospectively analyzed. Results In 332 cases, the usage rates of ACEI/ARB, β-blocker and MRA were respectively
85.9%, 74.7% and 94.4%. 56.9% of patients accepted the combination therapy of three types of neuroendocrine inhibi-
tors. The rates of reaching standard dose of ACEI/ARB, β-blocker and MRA were respectively 69.3% , 42.0% and
100.0%. Conclusion The usage rates of three types of neuroendocrine inhibitors in dilated cardiomyopathy patients are
high, but the combination use and the rates of reaching standard dose of ACEI /ARB and β-blockers are somewhat low.

      【Key words】 Dilated cardiomyopathy; Heart failure; Neuroendocrine inhibitors
·调查研究·
6350.2016.18.051